{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T23:46:13Z","timestamp":1648943173004},"reference-count":27,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.3892\/ol_00000014","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T20:53:32Z","timestamp":1257972812000},"page":"81-85","source":"Crossref","is-referenced-by-count":1,"title":["Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer"],"prefix":"10.3892","volume":"1","author":[{"given":"YASUHIRO","family":"INOUE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOJI","family":"TANAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUNICHIRO","family":"HIRO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUJI","family":"TOIYAMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIKAO","family":"MIKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASATO","family":"KUSUNOKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2010,1,1]]},"reference":[{"key":"key20180108105416_b1-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b2-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"key20180108105416_b3-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"key20180108105416_b4-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"De Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b5-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","article-title":"Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer","volume":"18","author":"Giacchetti","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b6-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00000658-198405000-00002","article-title":"The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment","volume":"199","author":"Wagner","year":"1984","journal-title":"Ann Surg"},{"key":"key20180108105416_b7-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project","volume":"10","year":"1992","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b8-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2004.03.104","article-title":"Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis","volume":"22","author":"Thirion","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b9-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000226725","article-title":"5-Fluorouracil by protracted venous infusion. A review of current progress","volume":"46","author":"Hansen","year":"1989","journal-title":"Oncology"},{"key":"key20180108105416_b10-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"DeGramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b11-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b12-ol-01-01-0081","first-page":"653","article-title":"Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression","volume":"13","author":"Kusunoki","year":"1998","journal-title":"Int J Oncol"},{"key":"key20180108105416_b13-ol-01-01-0081","first-page":"547","article-title":"The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas","volume":"6","author":"Kusunoki","year":"1998","journal-title":"Oncol Rep"},{"key":"key20180108105416_b14-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/1097-0142(20000915)89:6<1228::AID-CNCR6>3.0.CO;2-O","article-title":"Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases","volume":"15","author":"Kusunoki","year":"2000","journal-title":"Cancer"},{"key":"key20180108105416_b15-ol-01-01-0081","first-page":"1029","article-title":"Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy","volume":"1","author":"Yoshikawa","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108105416_b16-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1349-7006.1991.tb01873.x","article-title":"Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition","volume":"82","author":"Kubota","year":"1991","journal-title":"Jpn J Cancer Res"},{"key":"key20180108105416_b17-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key20180108105416_b18-ol-01-01-0081","volume-title":"NCI Common Toxicity Criteria Version 2.0","year":"1999"},{"key":"key20180108105416_b19-ol-01-01-0081","first-page":"1855","article-title":"Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules","volume":"52","author":"Aschele","year":"1992","journal-title":"Cancer Res"},{"key":"key20180108105416_b20-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/jnci\/85.23.1937","article-title":"Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells","volume":"85","author":"Sobrero","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"key20180108105416_b21-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1997.15.1.368","article-title":"Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation","volume":"15","author":"Sobrero","year":"1997","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b22-ol-01-01-0081","first-page":"763","article-title":"Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil","volume":"69","author":"Fujii","year":"1978","journal-title":"Gann"},{"key":"key20180108105416_b23-ol-01-01-0081","first-page":"209","article-title":"Effect of co-administration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents","volume":"70","author":"Fujii","year":"1979","journal-title":"Gann"},{"key":"key20180108105416_b24-ol-01-01-0081","first-page":"1571","article-title":"Improved survival using multi-modality therapy in patients with lung metastases from colorectal cancer: A preliminary study","volume":"14","author":"Inoue","year":"2005","journal-title":"Oncol Rep"},{"key":"key20180108105416_b25-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jjco\/hyp031","article-title":"A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy","volume":"39","author":"Inoue","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108105416_b26-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108105416_b27-ol-01-01-0081","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1158\/1078-0432.CCR-07-1529","article-title":"5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer","volume":"14","author":"Di Paolo","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol_00000014\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T14:20:50Z","timestamp":1515421250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol_00000014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1,1]]},"published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.3892\/ol_00000014"],"URL":"https:\/\/doi.org\/10.3892\/ol_00000014","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}